title: Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?
authors.affiliation: Authors' Affiliation: Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Eric R
authors.initials: ER
authors.lastname: Lutz
authors.affiliation: Authors' Affiliation: Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland ejaffee@jhmi.edu.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Jaffee
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular / Q000235:genetics / Q000276:immunology; D016233:Immunotherapy, Active / Q000379:methods*; D009154:Mutation / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D057285:Precision Medicine; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015395:Histocompatibility Antigens Class I